ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1428

Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis

Martin Soubrier1, Zuzana Tatar2, Maxime Chevreau3, Bruno Pereira4, Laure Gossec5, P Gaudin6 and Maxime Dougados7, 1COMEDRA trial group, Paris, France, 2Centre Jean Perrin, Clermont Ferrand, France, 3Rheumatology, CHU Sud Hospital, Grenoble, France, 4Clinical research department, Clermont-Ferrand, France, 5Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, 6CHU Hôpital Sud, Grenoble, France, 7RAID working group for EULAR, Zurich, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Co-morbidities, prevention and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose

Cardiovascular risk (CVR) is increased in RA and should be evaluated annually. EULAR recommends using the SCORE equation to calculate risk, after applying a multiplier of 1.5 in patients with RA who meet two of the following three criteria: disease duration > 10 years, rheumatoid factor or anti-CCP antibody positivity, presence of extra-articular manifestations. European guidelines (ESC) recommend statin therapy for subjects with high or very high risk i.e  when CVR calculated with the SCORE equation is ≥ 10% and LDL-cholesterol is ≥ 1.8 mmol/l, or when CVR is > 5% and < 10% and LDL-cholesterol is ≥ 2.5 mmol/l (1,2). Until now the Adult Treatment Panel -III (ATP-III) guidelines recommended the use of statin therapy for primary prevention on the basis of a combined assessment of LDL cholesterol and the 10-year risk of coronary heart disease as calculated with the use of the Framingham risk calculator. American recommendations (ACC/AHA) have recently changed and a new equation to assess overall CVR has been validated. Statin therapy is recommended for subjects aged 40-75 years when CVR is ≥ 7.5.

Assess the need for statin in an established RA cohort (COMEDRA study) according to ESC, ATP-III, and ACC/AHA guidelines with application of the multiplier proposed by EULAR, in patients aged 40 years or older without diabetes, overt cardiovascular disease (CVD) and statins.

Methods

COMEDRA is a multicentre French cohort study of comorbidities in patients with RA and a self-assessment of the disease. At inclusion, general characteristics (age, sex), duration of the disease and  treatments for the RA , cardiovascular risk factors (hypertension, diabetes, smoking habit, total, HDL and LDL cholesterol, obesity ), RA activity assessed using the DAS28VS, DAS28CRP, SDAI, CDAI, HAQ, ESR, CRP, RA antibodies were recorded for each patient.

Results

970 patients were included. 612 patients (82.7% women) with established RA (mean disease duration 11.3 [6.5 – 19.8] years) were analyzed (Exclusion age (n = 49); Diabetes or overt CVD (n = 65), statins (n = 168), incomplete data (n = 76)). RA was erosive in 450 (74.3 %) and 484 (79.1%) had positive RF or anti-CCP antibodies. 431 patients (70.4%) were treated with a biologic and 217 (35.6%) received glucocorticoids (mean, 5.34 ± 5.59 mg/day). 90 (14.7%) patients had a family history of early onset CVD, 147 (24.0%) were treated for hypertension, 100 (16.3%) were smokers.

 

Treatment recommendations based on Different Guidelines

 

ESC

ATP-III

ACC/AHA

Women (n = 506)

 

 

 

   Treatment recommended

7 (1.4)

50 (9.9)

155 (30.6)

   Treatment considered

241 (47.6)

57 (11.2)

292 (57.7)

    No treatment

257 (50.8)

399 (78.9)

59 (11.7)

Men (n = 106)

 

 

 

   Treatment recommended

9 (8.5)

47 (44.3)

76 (71.7)

   Treatment considered

80 (75.5)

21 (19.8)

29 (27.4)

   No treatment

17 (16)

38 (35.8)

1 (0.9)

 Conclusion

In this RA patient’s aged 40 years or older, proportion of individuals eligible for statins differed substantially among the guidelines.


Disclosure:

M. Soubrier,
None;

Z. Tatar,
None;

M. Chevreau,
None;

B. Pereira,
None;

L. Gossec,
None;

P. Gaudin,
None;

M. Dougados,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-application-of-the-european-society-cardiology-adult-treatment-panel-iii-and-accaha-guidelines-for-cardiovascular-disease-prevention-in-a-french-cohort-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences